Overview
- Anastrozole, a drug previously used to treat breast cancer, has now been licensed to prevent the disease, and will be offered to nearly 300,000 high-risk postmenopausal women in England, potentially preventing 8,000 cases.
- The drug works by reducing the amount of hormone oestrogen produced using an enzyme known as aromatase. It will be eligible for women with a family history of breast cancer or faulty genes that increase their risk.
- Studies indicate anastrozole can almost halve the chances of developing breast cancer if taken daily for five years. The drug's original license has been extended to be used as a preventative measure.
- The drug is now licensed for prevention after the NHS England established a new 'Medicines Repurposing Programme' to make full use of existing medicines in new ways. The drug is predicted to save the NHS £15 million in treatment costs.
- Anastrozole is off-patent, making it cost-efficient for the NHS. This new approach of repurposing drugs could pave the way for similar measures for other diseases and increase overall accessibility to preventative medication.